Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amphotericin B

FDA-approved product (ointment, topical), marketed as Abelcet, Ambisome, Amphotec and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amphotericin B
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Cryptococcal meningitis
  • Cryptococcosis
  • Fungal infectious disease
  • Histoplasmosis
  • Infection
  • Mucormycosis
  • Sporotrichosis
  • Visceral Leishmaniasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antibiotics
FDA pharmacologic class
Lipid-based Polyene Antifungal; Polyene Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC A01AB04; WHO ATC A07AA07; WHO ATC G01AA03; WHO ATC J02AA01; FDA class Lipid-based Polyene Antifungal; FDA class Polyene Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 1 lab record
Open Amphotericin B in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amphotericin B with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection

    NCT00003315 · start 1997-07

    Registered record
    Registry ID
    NCT00003315
    Conditions
    Infection
    Interventions
    sargramostim; liposomal amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-07
    Completion
    1997-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventionsargramostim; liposomal amphotericin B
    PhasePhase 3
    Registry statusCompleted

  • A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

    NCT00001065

    Registered record
    Registry ID
    NCT00001065
    Conditions
    Candidiasis, Oral; HIV Infections
    Interventions
    Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-04
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Oral; HIV Infections
    InterventionAmphotericin B
    PhasePhase 2
    Registry statusCompleted

  • A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

    NCT00002068

    Registered record
    Registry ID
    NCT00002068
    Conditions
    Meningitis, Cryptococcal; HIV Infections
    Interventions
    Fluconazole; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis, Cryptococcal; HIV Infections
    InterventionFluconazole; Amphotericin B
    PhaseNot applicable
    Registry statusCompleted

  • A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

    NCT00002277

    Registered record
    Registry ID
    NCT00002277
    Conditions
    Mycoses; HIV Infections
    Interventions
    Fluconazole; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses; HIV Infections
    InterventionFluconazole; Amphotericin B
    PhasePhase 3
    Registry statusCompleted

  • A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

    NCT00002306

    Registered record
    Registry ID
    NCT00002306
    Conditions
    Meningitis, Cryptococcal; HIV Infections
    Interventions
    Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis, Cryptococcal; HIV Infections
    InterventionFluconazole
    PhaseNot applicable
    Registry statusCompleted